Literature DB >> 8385973

Equipotent inhibition by R(-)-, S(+)- and racemic ibuprofen of human polymorphonuclear cell function in vitro.

M Villanueva1, R Heckenberger, H Strobach, M Palmér, K Schrör.   

Abstract

1. The effects of racemic (rac) ibuprofen and its S(+)- and R(-)-enantiomers on functions of human polymorphonuclear cells (PMN) and platelets were studied in vitro. 2. Rac-ibuprofen inhibited PMN functions (O2- generation, beta-glucuronidase release, LTB4 formation). Similar IC50 values (40-100 microM) were obtained for the S(+)- and R(-)-enantiomers. 3. All forms of ibuprofen inhibited cyclooxygenase-related platelet functions (aggregation, thromboxane formation). The S(+)-enantiomer was about twice as active as the racemate while the R(-)-enantiomer was at least 10-fold less active. This demonstrates that the S(+) is the only cyclooxygenase inhibitory component of the racemate. 4. The concentrations of rac-ibuprofen in PMN and platelets were similar to those in the incubation medium and represented equal concentrations of the enantiomers. This indicates that neither interconversion nor tissue accumulation of the compounds occurred. 5. These data indicate that antineutrophil effects of ibuprofen on human PMN are independent of cyclooxygenase inhibition. Therefore, R(-)-ibuprofen may be superior to the S(+)-isomer for the treatment of PMN-dependent inflammatory diseases. However, effective free drug concentrations may not be obtained in vivo.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8385973      PMCID: PMC1381568          DOI: 10.1111/j.1365-2125.1993.tb05690.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  33 in total

1.  [Pharmacokinetics and bioequivalence of two ibuprofen formulations].

Authors:  G Lenhard; U Kieferndorf; G Berner; B Engels; U Vögtle-Junkert
Journal:  Arzneimittelforschung       Date:  1990-12

Review 2.  Chirality in antirheumatic drugs.

Authors:  W F Kean; C J Lock; H E Howard-Lock
Journal:  Lancet       Date:  1991 Dec 21-28       Impact factor: 79.321

Review 3.  Clinical pharmacology through the looking glass: reflections on the racemate vs enantiomer debate.

Authors:  M S Lennard
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

4.  Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee.

Authors:  J D Bradley; K D Brandt; B P Katz; L A Kalasinski; S I Ryan
Journal:  N Engl J Med       Date:  1991-07-11       Impact factor: 91.245

5.  Ibuprofen prevents oxidant lung injury and in vitro lipid peroxidation by chelating iron.

Authors:  T P Kennedy; N V Rao; W Noah; J R Michael; M H Jafri; G H Gurtner; J R Hoidal
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

Review 6.  Dissociation between the antinociceptive and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs. A survey of their analgesic efficacy.

Authors:  K McCormack; K Brune
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

7.  Effect of racemic ibuprofen dose on the magnitude and duration of platelet cyclo-oxygenase inhibition: relationship between inhibition of thromboxane production and the plasma unbound concentration of S(+)-ibuprofen.

Authors:  A M Evans; R L Nation; L N Sansom; F Bochner; A A Somogyi
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

8.  Metabolic stereoisomeric inversion of ibuprofen in mammals.

Authors:  C S Chen; W R Shieh; P H Lu; S Harriman; C Y Chen
Journal:  Biochim Biophys Acta       Date:  1991-07-12

9.  Non-steroidal anti-inflammatory drugs: effects on a GTP binding protein within the neutrophil plasma membrane.

Authors:  S B Abramson; J Leszczynska-Piziak; K Haines; J Reibman
Journal:  Biochem Pharmacol       Date:  1991-06-01       Impact factor: 5.858

10.  Studies on the metabolism and chiral inversion of ibuprofen in isolated rat hepatocytes.

Authors:  S M Sanins; W J Adams; D G Kaiser; G W Halstead; T A Baillie
Journal:  Drug Metab Dispos       Date:  1990 Jul-Aug       Impact factor: 3.922

View more
  13 in total

Review 1.  Chirality and nonsteroidal anti-inflammatory drugs.

Authors:  P J Hayball
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 2.  Preclinical and clinical development of dexketoprofen.

Authors:  D Mauleón; R Artigas; M L García; G Carganico
Journal:  Drugs       Date:  1996       Impact factor: 9.546

3.  Mechanisms involved in the attenuation of intestinal toxicity induced by (S)-(+)-ketoprofen in re-fed rats.

Authors:  Ana I Nieto; Francesc Cabré; Francisco J Moreno; Catalina Alarcón de la Lastra
Journal:  Dig Dis Sci       Date:  2002-04       Impact factor: 3.199

Review 4.  Clinical pharmacokinetics of ibuprofen. The first 30 years.

Authors:  N M Davies
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

5.  Gastric toxicity of racemic ketoprofen and its enantiomers in rat: oxygen radical generation and COX-expression.

Authors:  C Alarcón de la Lastra; A Nieto; M J Martín; F Cabré; J M Herrerías; V Motilva
Journal:  Inflamm Res       Date:  2002-02       Impact factor: 4.575

6.  PharmGKB summary: ibuprofen pathways.

Authors:  Liudmila L Mazaleuskaya; Katherine N Theken; Li Gong; Caroline F Thorn; Garret A FitzGerald; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2015-02       Impact factor: 2.089

Review 7.  Ibuprofen: pharmacology, efficacy and safety.

Authors:  K D Rainsford
Journal:  Inflammopharmacology       Date:  2009-11-21       Impact factor: 4.473

8.  Leukocyte lipid body formation and eicosanoid generation: cyclooxygenase-independent inhibition by aspirin.

Authors:  P T Bozza; J L Payne; S G Morham; R Langenbach; O Smithies; P F Weller
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

9.  Stereoselective disposition of ibuprofen enantiomers in human cerebrospinal fluid.

Authors:  B Bannwarth; F Lapicque; F Pehourcq; P Gillet; T Schaeverbeke; C Laborde; J Dehais; A Gaucher; P Netter
Journal:  Br J Clin Pharmacol       Date:  1995-09       Impact factor: 4.335

10.  Dexibuprofen: pharmacology, therapeutic uses and safety.

Authors:  S T Kaehler; W Phleps; E Hesse
Journal:  Inflammopharmacology       Date:  2003       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.